Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
You may find more results for this query on our sister sites:
GenomeWeb
and
360Dx
.
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Partner Content
Virtual Molecular Tumor Board Series
Menu
Home
›
About Us
›
Our Staff
›
Greg Anderson
Greg Anderson
Chief Operating Officer
Phone Number
917-628-5903
Email
[email protected]
Breaking
News
Roche Withdraws Tecentriq for Bladder Cancer After FDA Accelerated Approval Review
FDA Approves Gilead's CAR T-cell Therapy Yescarta for Follicular Lymphoma
UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer
Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients
Amgen to Acquire Five Prime Therapeutics for $1.9B
Kronos Bio to Proceed With Phase III Trial of Entospletinib in NPM1-Mutated AML
